WE AIM FOR AN ACTIVE LIFESTYLE AND IMPROVED QUALITY OF LIFE FOR THE MILLIONS AFFECTED BY CHRONIC INFLAMMATORY DISEASES
MORE ABOUT US

WE DEVELOP AN ANTI-INFLAMMATORY DRUG WITH FIRST-IN-CLASS POTENTIAL

We aim to eliminate or alleviate painful symptoms for millions of patients suffering from chronic inflammatory diseases. Lipum has a biological anti-inflammatory drug candidate developed against Rheumatoid Arthritis (RA) – an autoimmune disease characterized by chronic inflammation of the joints. It often causes disability and lowers the quality of life for millions.

Treatment of other chronic inflammatory conditions is also explored. Related diseases are such as Crohn’s disease, ulcerative colitis, ankylosing spondylitis, and psoriatic arthritis.

Our biological anti-inflammatory drug candidate provides a novel mechanism of action. Therefore, it is assumed to have less adverse effects than current treatments in use.

THE STORY BEHIND LIPUM

Lipum was originally founded based on a discovery made by sci­entists at Umeå University.

The history of the innovation goes back 25 years when Olle Hernell, Prof. of Pediatrics, and his group was studying the nutrition of breast milk in newborns during early infancy, focusing on a protein that is now known as bile salt-stimulated lipase (BSSL).

Read more

Redeye Autoimmune & Inflammatory Disease Event

Watch Einar Ponténs presentation at the Redeye Autoimmune & Inflammatory Disease Event in front of 15 professional investors in person and online audience extended to 869 viewers.

Watch presentation »

SUBSCRIBE TO INFORMATION FROM LIPUM

PRESS RELEASES

2023-12-01 08:45 Ola Sandborgh takes office as CEO for Lipum AB today
Lipum AB (publ) is strengthening its leadership when going into phase II by appointing Ola Sandborgh as its new CEO where he takes over the helm from Einar...
2023-11-30 08:00 Lipum changes its liquidity provider to Carnegie Investment Bank AB Regulatory
Lipum AB (publ) has terminated the liquidity provider assignment with Erik Penser Bank AB and has appointed Carnegie Investment Bank AB as new liquidity...
2023-11-09 13:00 Lipum appoints Ola Sandborgh as new Chief Executive Officer Regulatory MAR
Lipum (publ), a clinical stage biopharmaceutical company focused on chronic inflammatory diseases, today announced that the Board of Directors has appointed...